Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis

Thoracic Cancer
Qiaoyun TanYuankai Shi

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical treatment of multiple cancers. Recent studies revealed the potential prognostic value of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in patients receiving ICIs; however, the results were inconsistent. We conducted a meta-analysis to identify the prognostic significance of baseline NLR and PLR in cancer patients treated with ICIs. We conducted a thorough literature search of PubMed, Embase, and Cochrane databases for studies dealing with the prognostic impact of pretreatment NLR and/or PLR levels in cancer patients treated with ICIs. The clinical outcomes were progression-free survival (PFS) and overall survival (OS). Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated, and sensitivity and subgroup analyses were performed to investigate heterogeneity. Seventeen articles involving 2092 patients were included in the final analysis. The pooled HRs of PFS and OS for NLR were 1.81(95% CI 1.36-2.41) and 2.26 (95% CI 1.68-3.03), respectively, suggesting that patients with higher baseline NLRs had significantly poorer PFS and OS. Similar results were detected in sensitivity and subgroup analyses. However, no signif...Continue Reading

References

Mar 23, 2010·Cell·Sergei I GrivennikovMichael Karin
Dec 30, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M Di GiacomoM Maio
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Apr 4, 2015·Science·Ton N Schumacher, Robert D Schreiber
Sep 8, 2015·Cell·Santiago ZelenayCaetano Reis e Sousa
Dec 30, 2015·Trends in Molecular Medicine·Dingzhi Wang, Raymond N DuBois
Apr 14, 2016·Seminars in Immunology·Katrin Moses, Sven Brandau
Apr 24, 2016·Trends in Immunology·Lauryn E Klevorn, Ryan M Teague
Apr 29, 2016·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Minkyu JungSang Joon Shin
Jan 10, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberCaroline Robert
Feb 12, 2017·Cell·Padmanee SharmaAntoni Ribas
Mar 4, 2017·Biochemical and Biophysical Research Communications·Hu LiuKai Lu
Mar 14, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Stephen J BagleyCorey J Langer
Mar 31, 2017·EBioMedicine·Michael R CassidyCharlotte Ariyan
May 4, 2017·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Qi-Tao HuangYan-Hong Yu
Aug 22, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Roger SunCharles Ferté
Aug 26, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Stefan DiemMartin Früh
Nov 4, 2017·Wiener klinische Wochenschrift·Christiane ThallingerChristoph Zielinski
Jan 11, 2018·The New England Journal of Medicine·Michael A PostowMatthew D Hellmann

❮ Previous
Next ❯

Citations

Oct 23, 2019·Cancer Immunology, Immunotherapy : CII·Marra Jai AghajaniTara Laurine Roberts
Aug 23, 2019·Liver International : Official Journal of the International Association for the Study of the Liver·Chandan SangheraDavid J Pinato
May 25, 2021·International Journal of Urology : Official Journal of the Japanese Urological Association·Takuma NaritaChikara Ohyama

❮ Previous
Next ❯

Software Mentioned

Stata

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.